Devlin Jodi's Form 4 filing
TriSalus Life Sciences, Inc. (TLSI) · filed May 21, 2025
- Accession no.
- 0001826667-25-000059
- Filed
- May 21, 2025
- Trade date
- May 19, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $24.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Devlin JodiCIK 0001992151 | Officer (Chief of Clinical Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 19, 2025 | Common Stock | AGrant or awardAcquired | +24,131 | $5.18 | +$124,998.58 | 57,528 | Direct | |
| May 19, 2025 | Common Stock | SSaleDisposed | −4,764 | $5.18 | −$24,677.52 | 52,764 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.